HU228764B1 - Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation - Google Patents

Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation Download PDF

Info

Publication number
HU228764B1
HU228764B1 HU9700579A HUP9700579A HU228764B1 HU 228764 B1 HU228764 B1 HU 228764B1 HU 9700579 A HU9700579 A HU 9700579A HU P9700579 A HUP9700579 A HU P9700579A HU 228764 B1 HU228764 B1 HU 228764B1
Authority
HU
Hungary
Prior art keywords
formula
compound
active ingredient
group
compounds
Prior art date
Application number
HU9700579A
Other languages
English (en)
Hungarian (hu)
Inventor
Klaus Dr Bosslet
Joerg Dr Czech
Jean-Claude Dr Florent
Manfred Dr Gerken
Claude Dr Monneret
Frederic Dr Schmidt
Rainer Dr Straub
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU228764(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HU9700579D0 publication Critical patent/HU9700579D0/hu
Publication of HUP9700579A2 publication Critical patent/HUP9700579A2/hu
Publication of HUP9700579A3 publication Critical patent/HUP9700579A3/hu
Publication of HU228764B1 publication Critical patent/HU228764B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9700579A 1996-03-12 1997-03-12 Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation HU228764B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (4)

Publication Number Publication Date
HU9700579D0 HU9700579D0 (en) 1997-04-28
HUP9700579A2 HUP9700579A2 (en) 1997-12-29
HUP9700579A3 HUP9700579A3 (en) 1999-05-28
HU228764B1 true HU228764B1 (en) 2013-05-28

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700579A HU228764B1 (en) 1996-03-12 1997-03-12 Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation

Country Status (24)

Country Link
US (1) US5935995A (enExample)
EP (1) EP0795334B1 (enExample)
JP (1) JP4392065B2 (enExample)
KR (1) KR100466467B1 (enExample)
CN (1) CN1168733C (enExample)
AT (1) ATE316799T1 (enExample)
AU (1) AU708202B2 (enExample)
BG (1) BG61900B1 (enExample)
BR (1) BRPI9701248B1 (enExample)
CA (1) CA2199664C (enExample)
CZ (1) CZ297994B6 (enExample)
DE (1) DE59712561D1 (enExample)
DK (1) DK0795334T3 (enExample)
ES (1) ES2257756T3 (enExample)
HU (1) HU228764B1 (enExample)
NO (1) NO320322B1 (enExample)
NZ (1) NZ314368A (enExample)
PL (1) PL189604B1 (enExample)
RO (1) RO120951B1 (enExample)
RU (1) RU2191021C2 (enExample)
SG (1) SG50011A1 (enExample)
SI (1) SI0795334T1 (enExample)
TR (1) TR199700178A2 (enExample)
UA (1) UA50719C2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
WO2000047236A1 (en) 1999-02-12 2000-08-17 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000066612A1 (en) 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
WO2003020029A1 (en) * 2001-08-30 2003-03-13 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to us28
AU2003244088A1 (en) * 2002-06-20 2004-01-06 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN102746336B (zh) * 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
AU2008236684B2 (en) * 2007-04-06 2013-04-18 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN104496982A (zh) * 2009-09-02 2015-04-08 奥克兰联合服务有限公司 激酶抑制剂、其前药形式及它们在治疗中的用途
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
KR102847342B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 자기-희생기를 포함하는 접합체 및 이의 제조방법
CA3006247A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
TWI859138B (zh) 2018-05-09 2024-10-21 韓商瑞嘉化學生物科學股份有限公司 與抗cd19抗體藥物結合物相關之組合物及方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
ATE123414T1 (de) * 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
RU2142937C1 (ru) * 1990-05-18 1999-12-20 Хехст АГ Амиды органических кислот, способ их получения и фармацевтическая композиция
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
ES2069955T3 (es) * 1991-10-25 1995-05-16 Tungsram Reszvenytarsasag Lampara de descarga de baja presion con un solo casquillo.
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
NO320322B1 (no) 2005-11-21
NO971116L (no) 1997-09-15
PL189604B1 (pl) 2005-08-31
US5935995A (en) 1999-08-10
RU2191021C2 (ru) 2002-10-20
BR9701248A (pt) 1999-10-13
MX9701832A (es) 1998-07-31
NZ314368A (en) 1998-10-28
ATE316799T1 (de) 2006-02-15
EP0795334A3 (de) 1997-09-24
TR199700178A2 (tr) 1997-09-21
CA2199664A1 (en) 1997-09-12
BRPI9701248B1 (pt) 2022-01-18
AU708202B2 (en) 1999-07-29
EP0795334B1 (de) 2006-02-01
AU1620597A (en) 1997-09-18
CN1163895A (zh) 1997-11-05
SI0795334T1 (sl) 2006-06-30
KR970065550A (ko) 1997-10-13
BG101290A (en) 1997-09-30
CN1168733C (zh) 2004-09-29
DK0795334T3 (da) 2006-06-06
BR9701248A8 (pt) 2013-06-18
BG61900B1 (bg) 1998-09-30
SG50011A1 (en) 1998-06-15
DE59712561D1 (de) 2006-04-13
KR100466467B1 (ko) 2005-06-29
EP0795334A2 (de) 1997-09-17
UA50719C2 (uk) 2002-11-15
RO120951B1 (ro) 2006-10-30
HUP9700579A3 (en) 1999-05-28
HUP9700579A2 (en) 1997-12-29
PL318878A1 (en) 1997-09-15
CA2199664C (en) 2008-05-20
NO971116D0 (no) 1997-03-11
HU9700579D0 (en) 1997-04-28
CZ74297A3 (en) 1997-09-17
CZ297994B6 (cs) 2007-05-16
JPH101495A (ja) 1998-01-06
JP4392065B2 (ja) 2009-12-24
ES2257756T3 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
HU228764B1 (en) Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation
JP3841311B2 (ja) プロドラッグ、その製造および医薬としての使用
US5728868A (en) Prodrugs of protein tyrosine kinase inhibitors
JP4430135B2 (ja) カチオン脂質複合体
KR20050113670A (ko) 암 치료를 위한 조성물 및 방법
Reux et al. Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives
AU2002358086B2 (en) Podophyllotoxins as antiproliferative agents
US8232254B2 (en) Colchicine neoglycosides and methods for their synthesis and use
CA3203849A1 (en) Dual-cleavage ester linkers for antibody-drug conjugates
Desbene et al. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy
US12458702B2 (en) Conjugate for targeting therapy
MXPA97001832A (en) New profarmacos for inflamator tumors and disease therapy
AU2022451890A1 (en) Conjugate for targeting therapy
Semakov et al. Low Molecular Weight Modifications of Anthracycline Antibiotics. Part II. Reactions by Other Positions (A Review)

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees